Edition:
India

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

3.43USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$3.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,571
52-wk High
$6.21
52-wk Low
$2.74

Latest Key Developments (Source: Significant Developments)

Casi Pharmaceuticals Inc - Board Unanimously Voted To Appoint (Wei) Larry Zhang As President
Thursday, 12 Sep 2019 

Sept 11 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS INC - BOARD UNANIMOUSLY VOTED TO APPOINT (WEI) LARRY ZHANG AS PRESIDENT.  Full Article

Casi Pharmaceuticals Inc - QTRLY Loss Per Share $0.16
Friday, 9 Aug 2019 

CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER AND FIRST HALF 2019 FINANCIAL AND BUSINESS RESULTS.CASI PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.16.  Full Article

CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize Anti-CD19 T-cell Therapy
Monday, 17 Jun 2019 

June 17 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ACQUIRES WORLDWIDE RIGHTS TO COMMERCIALIZE ANTI-CD19 T-CELL THERAPY.CASI PHARMACEUTICALS - SIGNING OF AGREEMENT FOR EXCLUSIVE WORLDWIDE RIGHTS TO AUTOLOGOUS ANTI-CD19 T-CELL THERAPY PRODUCT FROM JUVENTAS CELL THERAPY.CASI PHARMACEUTICALS INC - WILL BE RESPONSIBLE FOR PAYMENT OF CERTAIN FUTURE DEVELOPMENT MILESTONES AND SALES ROYALTIES..CASI PHARMACEUTICALS - IN CONNECTION WITH LICENSE, CASI PHARMACEUTICALS (WUXI) CO WILL INVEST RMB 80 MILLION IN JUVENTAS.  Full Article

CASI Pharmaceuticals Appoints Wei-Wu He As CEO
Tuesday, 2 Apr 2019 

April 2 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF WEI-WU HE, PH.D., EXECUTIVE CHAIRMAN, TO THE ROLE OF CHIEF EXECUTIVE OFFICER.CASI PHARMACEUTICALS INC -WEI-WU HE WILL CONTINUE TO SERVE AS CHAIRMAN OF BOARD OF DIRECTORS.CASI PHARMACEUTICALS INC - WEI HU HE SUCCEEDS KEN K. REN.CASI PHARMACEUTICALS INC - KEN K. REN WILL REMAIN ON COMPANY'S BOARD OF DIRECTORS..  Full Article

CASI Pharmaceuticals Q4 Loss Per Share $0.10
Friday, 29 Mar 2019 

March 29 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS RESULTS.Q4 LOSS PER SHARE $0.10.AS OF DECEMBER 31, 2018, CASI HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $84.2 MILLION..  Full Article

CASI Pharmaceuticals Announces China NMPA Approval Of CTA To Conduct Registration Trial For MARQIBO
Thursday, 7 Mar 2019 

March 7 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS - CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED CO'S CLINICAL TRIAL APPLICATION TO CONDUCT REGISTRATION TRIAL FOR MARQIBO.CASI PHARMACEUTICALS - IS CURRENTLY REVIEWING CERTAIN REQUIREMENTS PROVIDED BY CENTER FOR DRUG EVALUATION, A DIVISION OF NMPA.  Full Article

Casi Pharmaceuticals, Wuxi Jintou Huicun Investment Enterprise Will Establish JV
Wednesday, 21 Nov 2018 

Nov 20 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS INC - CO, WUXI JINTOU HUICUN INVESTMENT ENTERPRISE WILL ESTABLISH JOINT VENTURE IN JIANGSU PROVINCE, CHINA.CASI PHARMACEUTICALS - UNDER TERMS OF AGREEMENTS, WITHIN 60 DAYS, CO & WUXI JINTOU HUICUN INVESTMENT ENTERPRISE WILL ESTABLISH THE JOINT VENTURE.CASI PHARMACEUTICALS INC - WUXI LP AGREED TO CONTRIBUTE EQUIVALENT IN RMB OF USD $20 MILLION IN CASH FOR 20PCT OF THE EQUITY OF THE JOINT VENTURE.CASI PHARMACEUTICALS INC - CO WILL INVEST, OVER TIME, $80 MILLION, ACCOUNTING FOR 80PCT OF THE EQUITY IN THE JOINT VENTURE.  Full Article

CASI Pharmaceuticals Acquires HBV ANDA From Laurus Labs Ltd
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Laurus Labs Ltd ::CASI PHARMACEUTICALS ACQUIRES HBV ANDA FROM LAURUS LABS LIMITED.CASI PHARMACEUTICALS INC - CASI WILL MAKE CERTAIN UPFRONT AND MILESTONE PAYMENTS IN DIFFERENT PHASES.  Full Article

CASI Pharmaceuticals Announces $48.5 Mln Private Placement
Friday, 14 Sep 2018 

Sept 14 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES $48.5 MILLION PRIVATE PLACEMENT.CASI PHARMACEUTICALS ANNOUNCES $48.5 MILLION PRIVATE PLACEMENT.CASI PHARMACEUTICALS INC - PURCHASE PRICE FOR EACH SHARE OF COMMON STOCK AND WARRANT IS $5.36.CASI PHARMACEUTICALS - ENTERED DEFINITIVE SECURITIES PURCHASE AGREEMENTS UNDER WHICH CO TO ISSUE 9 MILLION SHARES OF COMMON STOCK.CASI PHARMACEUTICALS - UNDER AGREEMENT CO TO ALSO ISSUE ACCOMPANYING WARRANTS TO PURCHASE 2.7 MILLION SHARES.  Full Article

CASI Pharmaceuticals Q2 Loss Per Share $0.07
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER AND FIRST HALF 2018 FINANCIAL AND BUSINESS RESULTS.CASI PHARMACEUTICALS INC - CFDA REVIEW IN PROGRESS FOR MARQIBO AND ZEVALIN.CASI PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.07.  Full Article